← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSTIMULANTS › IMMUNOSTIMULANTS › Colony stimulating factors
efbemalenograstim alfa
L03AA18
Forms & Strengths
- Injection: 6.4 mg/0.6 mL
- Solution for injection: 6.4 mg/0.6 mL
Adult Dosing
- 10 mcg/kg once daily for 4-8 days
- Dose depends on the indication and neutrophil count
Pediatric Dosing
- 10 mcg/kg once daily for 4-8 days, same as adult dosing in pediatric patients >= 45 kg
- Consult the prescribing information for specific dosing recommendations for pediatric patients < 45 kg
Indications
- Neutropenia secondary to chemotherapy
- Neutropenia in patients with acute myeloid leukemia receiving induction or consolidation chemotherapy
- Persistent neutropenia in patients with advanced HIV infection
Mechanism of Action
- Stimulates the production of neutrophils by binding to the G-CSF receptor
- Increases neutrophil count in the blood, reducing the incidence of infection
Contraindications
- Hypersensitivity to efbemalenograstim alfa or other G-CSF products
- Sickle cell disease crisis
Adverse Reactions
- Bone pain
- Musculoskeletal pain
- Headache
- Nausea and vomiting
- Fatigue
- Pyrexia
Drug Interactions
- Lithium: may increase white blood cell count
- Cyclophosphamide: may prolong neutropenia duration
Curated Content: Needs Vetting Before Put to Clinical Use